Baudax Bio Inc
Change company Symbol lookup
Select an option...
BXRX Baudax Bio Inc
ZM Zoom Video Communications Inc
T AT&T Inc
PBCT People's United Financial Inc
PHK PIMCO High Income Fund
BAC Bank of America Corp
BHF Brighthouse Financial Inc
CTBI Community Trust Bancorp Inc
$NYLGCAPT NYSE U.S. Large Cap Equal Weight Ind

Company profile

Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.

Day's Change
0.13 (3.52%)
B/A Size
Day's High
Day's Low

Today's volume of 194,250 shares is on pace to be much lighter than BXRX's 10-day average volume of 982,021 shares.


Tesla upgraded to neutral from underperform at BofA after stock almost halved in a month

10:07 am ET March 18, 2020 (MarketWatch)

BofA Securities upgraded the stock of Tesla Inc. (TSLA) to neutral from underperform on Wednesday, after it almost halved in the space of a month. Still, "while we continue to view TSLA as a trailblazer in the electric vehicle (EV) market, we believe investor optimism around the company and its business/financial future remains overhyped and litany of risks remain underappreciated, which keeps us relatively cautious on the stock despite the upgrade," analysts led by John Murphy wrote in a note to clients. The bank raised its stock price target to $500 from $370. "What the run up in TSLA stock from $300/sh to $900/sh+ in the span of 3 months has proven, however, is that valuation is a self-fulfilling prophecy of sorts; and we consider such "peak" valuation levels in our bull case scenarios, as well as a slightly higher probability of being achieved," said the note. Among the risk factors BofA identifed are that profitability and cash flow are not good or consistent; the company is still not self funding after a decade; credit investors are skeptical, but with equity cushion, have hopped on the bandwagon; "creative accounting and presentation helps on a transitory basis," and finally momentum buying is helping for now but a rotaiton of value stocks "could be painful." Tesla shares were down 6%, but have gained 50% in the last 12 months, while the S&P 500 has fallen 11%.

-Ciara Linnane; 415-439-6400;

(END) Dow Jones Newswires

March 18, 2020 10:07 ET (14:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.